ClinicalTrials.gg
CompletedNCT06143670Updated Mar 21, 2025Results posted

A Clinical Study Investigating the Effects of a Dentifrice Containing 0.454% Stannous Fluoride on Gingivitis Treatment and Plaque Reduction When Used Twice Daily for 12 Weeks

An interventional study of Stannous fluoride toothpaste and Sodium fluoride toothpaste in Gingivitis, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-21.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing Tin Fluorides in Gingivitis — 1 open to participants now, 3 under way, none of them phase 3. Tin Fluorides · Gingivitis.

Enrollment
5th of 23
159 · median 115
Started
2023
with 1 other
No phase
10 of 23
none open now
Registered
16th of 23
by date
Lead sponsor
1 of 23
HALEON

Among the 23 studies testing Tin Fluorides in Gingivitis, this one is the 5th largest by enrollment, is one of 2 that started in 2023, is one of 10 with no phase, and was the 16th registered.

Gingivitis

631 studies on the registry are indexed under Gingivitis; 107 are open to participants now.

Browse Gingivitis studies →

Open to participants now

1 of the 23 studies testing Tin Fluorides in Gingivitis is open now. Recruiting first, the newest first:

About Tin Fluorides

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Gingivitis studies recruiting now, 15 (28%) set no upper age limit and 36 (68%) stop at 75 or younger; 11 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing Tin Fluorides in Gingivitis, or all of them as a file.
02

Study summary

The purpose of this clinical study is to investigate the efficacy of a dentifrice containing 0.454 percent (%) weight by weight (w/w) stannous fluoride (SnF2), on gingivitis treatment and plaque reduction, compared to a regular fluoride dentifrice after 12 weeks twice daily brushing in a population of clinically diagnosed gingivitis without undergoing dental prophylaxis.

Read the detailed description

This will be a single center, randomized, controlled, single blind (examiner blind), two-treatment arm, parallel study. Study participants will be over 18 years old, non-smokers, in good general health with clinically measurable levels of gingivitis that meet all study criteria at the Screening and Baseline visits. Approximately 160 participants (approximately 80 per group) will be randomized to ensure approximately 144 evaluable participants (approximately 72 per group) complete the study.

03

Conditions studied

  • Gingivitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Participant is of either sex and any gender who, at the time of screening, is at least 18 years old, inclusive.
  • A participant who is willing and able to comply with scheduled visits, treatment plan, and other study procedures.
  • A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no /relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the participant's ability to understand and follow study procedures and requirements.
  • Participant oral health that meets all the following:

At Screening (Visit 1):

  1. Participant with at least 20 natural, permanent teeth.
  2. Participant with at least 40 evaluable surfaces for MGI, BI, and TPI (An evaluable surface is defined as having two thirds of the natural tooth surface gradable for the selected clinical indices. The following will not be included in the evaluable surface count: third molars; fully crowned/extensively restored, grossly carious, orthodontically banded/bonded or abutment teeth; surfaces with calculus deposits which, in the opinion of the clinical examiner, would interfere with the baseline assessments of the selected clinical indices).
  3. A participant with plaque-induced gingivitis, in the opinion of the clinical examiner, as confirmed by a gross visual examination.

    At Baseline (Visit 2):

  4. A participant with ongoing hard tissue eligibility and, in the opinion of the clinical examiner, at least 40 evaluable surfaces.
  5. A participant with 10% to 30% bleeding sites (following BI).
  6. A participant with mean whole mouth TPI score >=1.5.

Exclusion criteria

Exclusion Criteria:

  • A participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a sponsor's employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant who has any other clinical serious or unstable conditions (for example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) which could have affected study outcomes and/or participant safety.
  • A participant who is a pregnant female (self-reported) or is intending to become pregnant over the duration of the study.
  • A participant who is a breastfeeding female.
  • A participant who is known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • A participant who is unwilling or unable to comply with the lifestyle considerations.
  • Participant who is a current smoker or an ex-smoker who stopped within 6 months of Screening.
  • Participant who is using smokeless forms of tobacco (for example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).
  • A participant who is diagnosed xerostomia or is taking any medication that in the view of the investigator is causing xerostomia.
  • A participant who has a medical condition which could have directly influenced gingival bleeding (for example, type 2 diabetes).
  • A participant who has a bleeding disorder that could have affected study outcomes and/or participant safety.
  • A participant who has a recent history (within the last year) of alcohol or other substance abuse.
  • A participant who has a severe oral condition (for example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  • Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
  • Medication exclusions at screening (Visit 1):

    1. A participant using any antibiotic medication within 14 days prior to screening or at any time during the study.
    2. A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
    3. A participant currently taking a systemic medication (for example, anti-inflammatory, anticoagulant, ) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (for example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
  • Medication exclusions at Baseline (Visit 2):

    1. A participant who has taken (in the previous 14 days), any antibiotics.
    2. A participant who has taken (in the previous 14 days) a systemic medication (for example, anti-inflammatory, anti-coagulant, immunosuppressants) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (for example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
    3. A participant who has used an antibacterial dentifrice or mouthwash (for example, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, in the period between Screening and the Baseline visit.
  • Periodontal exclusions:

    1. A participant who shows signs of active periodontitis (with probing pocket depths greater than [>] 3mm).
    2. A participant who is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.
    3. A participant who has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.
  • Dental Exclusions:

    1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    2. A participant who has dentures (partial or full).
    3. A participant who has an orthodontic appliance (bands, appliances, or fixed/ removable retainers).
    4. A participant who received orthodontic therapy within 3 months of Screening.
    5. A participant who has numerous restorations in a poor state of repair.
    6. A participant who has any dental condition (for example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    7. A participant who has had dental prophylaxis within 12 weeks of Screening.
    8. A participant who has had teeth bleaching within 12 weeks of Screening.
    9. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.
  • A participant who has previously been enrolled in this study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Test Product

    Participants will be instructed to brush their teeth with full ribbon of toothpaste (0.454% w/w SnF2) on head of toothbrush provided for at least one (timed) minute twice a day (morning and evening) for 12 weeks.

    Drug: Stannous fluoride toothpaste

  • Active comparator
    Negative Control

    Participants will be instructed to brush their teeth with full ribbon of toothpaste (0.243% w/w Sodium fluoride) on head of toothbrush provided for at least one (timed) minute twice a day (morning and evening) for 12 weeks.

    Drug: Sodium fluoride toothpaste

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Mean Change From Baseline in the Number of Bleeding Sites (NBS) at Week 12

    The NBS were calculated using the bleeding index (BI) assessment. BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth using PCP11.5B Hu-Friedy Qulix Color Coded probe. The probe was gently inserted into the gingival crevice to a depth of approximately 1 millimeter (mm) and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. NBS for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival condition.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Adjusted Mean Change From Baseline in the NBS at Week 12 (Test Product Versus [vs.] Reference Product)

    The NBS were calculated using the BI assessment. BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth using PCP11.5B Hu-Friedy Qulix Color Coded probe. The probe was gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. NBS for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival condition.

    Time frame: Baseline and Week 12

  2. Adjusted Mean Change From Baseline in the NBS at Week 3 and Week 6 (Test Product vs. Reference Product)

    The NBS were calculated using the BI assessment. BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth using PCP11.5B Hu-Friedy Qulix Color Coded probe. The probe was gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. NBS for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival condition.

    Time frame: Baseline, Week 3 and Week 6

  3. Adjusted Mean Change From Baseline in Mean Overall Turesky Plaque Index (TPI) at Weeks 3, 6 and 12 (Test Product vs. Reference Product)

    TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth. The plaque was first disclosed using a plaque disclosing dye solution, disclosed plaque was then scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering less than one third of the tooth surface; 4=Plaque covering more than one third but less than two thirds of the tooth surface; 5=Plaque covering more than two thirds of the tooth surface. Overall TPI score for each participant=Sum of index values over all evaluable tooth sites (sites scored as 0 to 5), divided by the number of evaluable tooth sites and ranged from 0 to 5. Lower score=better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).

    Time frame: Baseline, Weeks 3, 6 and 12

  4. Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)

    TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth. The plaque was first disclosed using a plaque disclosing dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering less than one third of the tooth surface; 4=Plaque covering more than one third but less than two thirds of the tooth surface; 5=Plaque covering more than two thirds of the tooth surface. Interproximal TPI score for each participant=Sum of index values over all evaluable distal and mesial tooth sites, divided by the number of evaluable distal and mesial tooth sites and ranged from 0 to 5. Lower score=better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).

    Time frame: Baseline, Weeks 3, 6 and 12

  5. Adjusted Mean Change From Baseline in BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)

    BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. BI was assessed on the facial and lingual gingival surfaces of each scorable tooth using PCP11.5B Hu-Friedy Qulix Color Coded probe. Gingival bleeding was scored on a 3-points scale with scores ranging from 0 to 2, where 0=No bleeding after 30 seconds, 1=Bleeding observed within 30 seconds of probing, 2=Bleeding observed immediately on probing. BI score for each participant=sum of index values over all evaluable tooth sites (those scored as 0, 1, or 2), divided by the number of evaluable tooth sites. Lower score=better outcome. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline=Day 0. A negative change from Baseline indicated improvement in gingival condition.

    Time frame: Baseline, Weeks 3, 6 and 12

  6. Adjusted Mean Change From Baseline in Modified Gingival Index (MGI) at Weeks 3, 6 and 12 (Test Product vs. Reference Product)

    MGI assessment is a non-invasive evaluation which focuses on visual symptoms of gingivitis (example, redness, texture, edema). MGI was assessed on facial and lingual surfaces of each scorable tooth and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in color, little change in color; little change in texture of any portion of marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline \[Day 0\] value. A negative change from Baseline indicated improvement in symptoms.

    Time frame: Baseline, Weeks 3, 6 and 12

07

Results

Posted Mar 21, 2025

Participant flow

This study was conducted at a single center in the United States.

Participant flow — Overall Study
MilestoneTest ProductReference Product (Negative Control)
Started7676
Completed7375
Not completed31
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject30

Outcome measures

PrimaryAdjusted Mean Change From Baseline in the Number of Bleeding Sites (NBS) at Week 12

The NBS were calculated using the bleeding index (BI) assessment. BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth using PCP11.5B Hu-Friedy Qulix Color Coded probe. The probe was gently inserted into the gingival crevice to a depth of approximately 1 millimeter (mm) and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. NBS for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival condition.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · bleeding sites
Adjusted Mean Change From Baseline in the Number of Bleeding Sites (NBS) at Week 12
bleeding sitesTest Product
Adjusted Mean Change From Baseline in the Number of Bleeding Sites (NBS) at Week 12-14.6 ± 0.99
Statistical analysis
  • Test Product · Mixed Model with Repeated Measures · p = <0.0001
SecondaryAdjusted Mean Change From Baseline in the NBS at Week 12 (Test Product Versus [vs.] Reference Product)

The NBS were calculated using the BI assessment. BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth using PCP11.5B Hu-Friedy Qulix Color Coded probe. The probe was gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. NBS for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at Week 12. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival condition.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · bleeding sites
Adjusted Mean Change From Baseline in the NBS at Week 12 (Test Product Versus [vs.] Reference Product)
bleeding sitesTest ProductReference Product (Negative Control)
Adjusted Mean Change From Baseline in the NBS at Week 12 (Test Product Versus [vs.] Reference Product)-14.6 ± 0.992.2 ± 0.98
Statistical analysis
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -16.9 · 95% CI -19.6 to -14.1Adjusted mean difference was calculated as test product minus reference product.
SecondaryAdjusted Mean Change From Baseline in the NBS at Week 3 and Week 6 (Test Product vs. Reference Product)

The NBS were calculated using the BI assessment. BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. The BI was assessed on the facial and lingual gingival surfaces of each scorable tooth using PCP11.5B Hu-Friedy Qulix Color Coded probe. The probe was gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. NBS for each participant was calculated as the number of evaluable tooth sites with bleeding observed immediately on probing or within 30 seconds of probing. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline was defined as Day 0. A negative change from Baseline indicated improvement in gingival condition.

Time frame:
Baseline, Week 3 and Week 6
Reported as:
Least squares mean · bleeding sites
Adjusted Mean Change From Baseline in the NBS at Week 3 and Week 6 (Test Product vs. Reference Product)
bleeding sitesTest ProductReference Product (Negative Control)
Change from Baseline at Week 3-14.8 ± 1.051.2 ± 1.01
Change from Baseline at Week 6-16.7 ± 0.840.9 ± 0.82
Statistical analysis
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -16.0 · 95% CI -18.9 to -13.1Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -17.6 · 95% CI -19.9 to -15.3Adjusted mean difference was calculated as test product minus reference product.
SecondaryAdjusted Mean Change From Baseline in Mean Overall Turesky Plaque Index (TPI) at Weeks 3, 6 and 12 (Test Product vs. Reference Product)

TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth. The plaque was first disclosed using a plaque disclosing dye solution, disclosed plaque was then scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering less than one third of the tooth surface; 4=Plaque covering more than one third but less than two thirds of the tooth surface; 5=Plaque covering more than two thirds of the tooth surface. Overall TPI score for each participant=Sum of index values over all evaluable tooth sites (sites scored as 0 to 5), divided by the number of evaluable tooth sites and ranged from 0 to 5. Lower score=better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).

Time frame:
Baseline, Weeks 3, 6 and 12
Reported as:
Least squares mean · score on a scale
Adjusted Mean Change From Baseline in Mean Overall Turesky Plaque Index (TPI) at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
score on a scaleTest ProductReference Product (Negative Control)
Change from Baseline at Week 3-0.30 ± 0.026-0.02 ± 0.025
Change from Baseline at Week 6-0.29 ± 0.023-0.10 ± 0.023
Change from Baseline at Week 12-0.32 ± 0.025-0.03 ± 0.024
Statistical analysis
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.28 · 95% CI -0.35 to -0.20Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.20 · 95% CI -0.26 to -0.13Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.29 · 95% CI -0.36 to -0.22Adjusted mean difference was calculated as test product minus reference product.
SecondaryAdjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)

TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth. The plaque was first disclosed using a plaque disclosing dye solution and scored on a 6-point scale ranging from 0 to 5, where 0=No plaque; 1=Separate flecks of plaque at the cervical margin; 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3=Band of plaque wider than 1 mm but covering less than one third of the tooth surface; 4=Plaque covering more than one third but less than two thirds of the tooth surface; 5=Plaque covering more than two thirds of the tooth surface. Interproximal TPI score for each participant=Sum of index values over all evaluable distal and mesial tooth sites, divided by the number of evaluable distal and mesial tooth sites and ranged from 0 to 5. Lower score=better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline value. Baseline=Day 0. A negative change from Baseline indicated improvement (less plaque accumulation).

Time frame:
Baseline, Weeks 3, 6 and 12
Reported as:
Least squares mean · score on a scale
Adjusted Mean Change From Baseline in Mean Interproximal TPI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
score on a scaleTest ProductReference Product (Negative Control)
Change from Baseline at Week 3-0.23 ± 0.022-0.02 ± 0.021
Change from Baseline at Week 6-0.25 ± 0.020-0.09 ± 0.019
Change from Baseline at Week 12-0.28 ± 0.022-0.04 ± 0.021
Statistical analysis
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.22 · 95% CI -0.28 to -0.16Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.16 · 95% CI -0.21 to -0.10Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.24 · 95% CI -0.30 to -0.18Adjusted mean difference was calculated as test product minus reference product.
SecondaryAdjusted Mean Change From Baseline in BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)

BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. BI was assessed on the facial and lingual gingival surfaces of each scorable tooth using PCP11.5B Hu-Friedy Qulix Color Coded probe. Gingival bleeding was scored on a 3-points scale with scores ranging from 0 to 2, where 0=No bleeding after 30 seconds, 1=Bleeding observed within 30 seconds of probing, 2=Bleeding observed immediately on probing. BI score for each participant=sum of index values over all evaluable tooth sites (those scored as 0, 1, or 2), divided by the number of evaluable tooth sites. Lower score=better outcome. Change from Baseline was calculated by subtracting the Baseline value from the value at each indicated timepoint. Baseline=Day 0. A negative change from Baseline indicated improvement in gingival condition.

Time frame:
Baseline, Weeks 3, 6 and 12
Reported as:
Least squares mean · score on a scale
Adjusted Mean Change From Baseline in BI at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
score on a scaleTest ProductReference Product (Negative Control)
Change from Baseline at Week 3-0.12 ± 0.0090.01 ± 0.009
Change from Baseline at Week 6-0.14 ± 0.0070.01 ± 0.007
Change from Baseline at Week 12-0.12 ± 0.0090.01 ± 0.009
Statistical analysis
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.12 · 95% CI -0.15 to -0.10Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.15 · 95% CI -0.17 to -0.13Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.14 · 95% CI -0.16 to -0.11Adjusted mean difference was calculated as test product minus reference product.
SecondaryAdjusted Mean Change From Baseline in Modified Gingival Index (MGI) at Weeks 3, 6 and 12 (Test Product vs. Reference Product)

MGI assessment is a non-invasive evaluation which focuses on visual symptoms of gingivitis (example, redness, texture, edema). MGI was assessed on facial and lingual surfaces of each scorable tooth and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in color, little change in color; little change in texture of any portion of marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated better outcome. Change from Baseline=Value at each indicated timepoint minus Baseline \[Day 0\] value. A negative change from Baseline indicated improvement in symptoms.

Time frame:
Baseline, Weeks 3, 6 and 12
Reported as:
Least squares mean · score on a scale
Adjusted Mean Change From Baseline in Modified Gingival Index (MGI) at Weeks 3, 6 and 12 (Test Product vs. Reference Product)
score on a scaleTest ProductReference Product (Negative Control)
Change from Baseline at Week 3-0.51 ± 0.0370.12 ± 0.036
Change from Baseline at Week 6-0.71 ± 0.032-0.07 ± 0.032
Change from Baseline at Week 12-0.71 ± 0.034-0.03 ± 0.034
Statistical analysis
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.64 · 95% CI -0.74 to -0.53Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.65 · 95% CI -0.74 to -0.56Adjusted mean difference was calculated as test product minus reference product.
  • Test Product vs Reference Product (Negative Control) · Mixed Model with Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.67 · 95% CI -0.77 to -0.58Adjusted mean difference was calculated as test product minus reference product.

Adverse events

Collected over From signing of informed consent form until 5 days after last administration of study product or last study procedure (up to approximately 111 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product0/76 (0%)0/76 (0%)5/76 (6.6%)
Reference Product (Negative Control)0/76 (0%)0/76 (0%)7/76 (9.2%)
Most frequent other events
Most frequent other events
EventTest ProductReference Product (Negative Control)
ORAL MUCOSAL EXFOLIATIONGastrointestinal disorders4/762/76
APHTHOUS ULCERGastrointestinal disorders1/762/76
HYPERAESTHESIA TEETHGastrointestinal disorders0/761/76
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations0/761/76
MOUTH INJURYInjury, poisoning and procedural complications0/761/76

Baseline characteristics

Safety Population included all randomized participants who received at least one dose of the study product.

Age, Continuous
Age, Continuous(years)Test ProductReference Product (Negative Control)Total
Mean47.8 ± 14.0050.5 ± 13.0449.2 ± 13.55
Sex: Female, Male
Sex: Female, Male(Participants)Test ProductReference Product (Negative Control)Total
Female5960119
Male171633
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test ProductReference Product (Negative Control)Total
Hispanic or Latino336
Not Hispanic or Latino7373146
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Test ProductReference Product (Negative Control)Total
African American/African Heritage8917
American Indian or Alaskan Native101
White - Arabic/North African Heritage202
White - White/Caucasian/European Heritage6465129
Multiple123
08

Study locations

1 site
  • Salus Research
    Fort Wayne, Indiana 46825, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2024, 3 months.

Results were first posted in Mar 2025, 1 year after primary completion.

Of 53 industry-sponsored interventional studies with no phase under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 5. This study's 3 months is close to that.

Counting every sponsor, half of 257 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2023
First posted
Nov 22, 2023
StartActual
Nov 29, 2023
Primary completionActual
Mar 12, 2024
CompletionActual
Mar 12, 2024
Results first posted
Mar 21, 2025
Last update
Mar 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06143670
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Nov 22, 2023
Start date
Nov 29, 2023
Primary completion
Mar 12, 2024
Completion
Mar 12, 2024
Results posted
Mar 21, 2025
Last update
Mar 21, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion